Analysts Are Bullish on These Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Altimmune (ALT)

TipRanksOct 9 20:00

Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants

Secondary analysis of the Phase 3 MAESTRO-NASH trial demonstrated Rezdiffra improved histology and MRI-PDFF across common genetic variants associated with MASH progression CONSHOHOCKEN, Pa., Oct. 06,

GlobeNewswireOct 6 20:00

Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $962

Barclays analyst Eliana Merle maintains $Madrigal Pharmaceuticals(MDGL.US)$ with a buy rating, and maintains the target price at $962.According to TipRanks data, the analyst has a success rate of 41.1

Futu NewsSep 30 17:31

Form 144 | Madrigal Pharmaceuticals(MDGL.US) Director Proposes to Sell 25.83 Million in Common Stocks

SEC FILLINGS DISCLOSED/ Sep 28, Madrigal Pharmaceuticals(MDGL.US) Director PAUL FRIEDMAN intends to sell 50,000 shares of its common stock on Sep 28, with a total market value of approximately $25.83 million.

Futu NewsSep 29 04:20

HCA, Tenet, CoreWeave, Microsoft, Madrigal Trending With Analysts

TipRanksSep 26 17:01

Goldman Sachs Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $704

Goldman Sachs analyst Andrea Newkirk maintains $Madrigal Pharmaceuticals(MDGL.US)$ with a buy rating, and adjusts the target price from $540 to $704.According to TipRanks data, the analyst has a

Futu NewsSep 24 16:32